

15 May 2024 | News

## **China Biotech Podcast: BIOSECURE Markup, Biotech Pipeline Updates**

by Brian Yang

As the proposed US BIOSECURE Act heads to a full House Oversight Committee vote, *Scrip*'s China-based editors Brian Yang and Dexter Yan, together and guest Derrick Gingery from the *Pink Sheet*, discuss the implications and potential outcomes for the biopharma sector and factors behind the "biotech decoupling" trend. Dexter also shares insights from his recent coverage of antibody-drug conjugate R&D updates by Chinese companies.

5\implies 5\implies 15\implies 15

The US Congress Oversight Committee is scheduled to hold a full vote on the planned BIOSECURE Act on 15 May, with the results expected to be less than surprising. The proposed legislation has attracted much attention and discussion, particularly for its potential impact on business relationships in the biopharma sector.

In this latest podcast episode, China-based editor Brian Yang discusses with guest speaker, Derrick Gingery from the *Pink Sheet* in the US, what is behind the "biotech decoupling" trend, the likely potential outcomes of the vote and next steps, as well as the implications for the biopharma sector.

Shanghai-based Scrip editor Dexter Yan also discusses with Brian his recent coverage of Chinese



biotech pipeline updates in the CNS area and for antibody-drug conjugates.

Stories discussed in this episode:

(Also see "<u>US FDA Asked To Tighten China Risk Control By Legislators As Markup Looms</u>" - Pink Sheet, 10 May, 2024.)

(Also see "BIOSECURE: What's Coming Next?" - Pink Sheet, 10 Apr, 2024.)

(Also see "BIOSECURE Act Update Offers Biotech Companies Eight Years to Divest Contracts With Firms Of 'Concern'" - Pink Sheet, 10 May, 2024.)

(Also see "Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive" - Scrip, 8 May, 2024.)

Click here to explore this interactive content online